Press Releases

Date Title
Toggle Summary Kura Oncology Announces License Agreement with Janssen Pharmaceutica for Development and Commercialization of Tipifarnib; Closes $60 Million Private Placement and Completes Reverse Merger
LA JOLLA, March 12, 2015 – Kura Oncology, Inc. (“Kura Oncology” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced several milestones.